These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

668 related items for PubMed ID: 26115659

  • 1. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
    Kang MG, Kim HR, Seo BY, Lee JH, Choi SY, Kim SH, Shin JH, Suh SP, Ahn JS, Shin MG.
    BMC Cancer; 2015 Jun 27; 15():484. PubMed ID: 26115659
    [Abstract] [Full Text] [Related]

  • 2. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance.
    Patnaik MM, Lasho TL, Finke CM, Hanson CA, Hodnefield JM, Knudson RA, Ketterling RP, Pardanani A, Tefferi A.
    Am J Hematol; 2013 Mar 27; 88(3):201-6. PubMed ID: 23335386
    [Abstract] [Full Text] [Related]

  • 3. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
    Hong JY, Seo JY, Kim SH, Jung HA, Park S, Kim K, Jung CW, Kim JS, Park JS, Kim HJ, Jang JH.
    Anticancer Res; 2015 May 27; 35(5):3081-9. PubMed ID: 25964599
    [Abstract] [Full Text] [Related]

  • 4. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.
    Makishima H, Visconte V, Sakaguchi H, Jankowska AM, Abu Kar S, Jerez A, Przychodzen B, Bupathi M, Guinta K, Afable MG, Sekeres MA, Padgett RA, Tiu RV, Maciejewski JP.
    Blood; 2012 Apr 05; 119(14):3203-10. PubMed ID: 22323480
    [Abstract] [Full Text] [Related]

  • 5. Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors.
    Je EM, Yoo NJ, Kim YJ, Kim MS, Lee SH.
    Int J Cancer; 2013 Jul 05; 133(1):260-5. PubMed ID: 23280334
    [Abstract] [Full Text] [Related]

  • 6. [Mutational analysis of RNA splicing machinery genes SF3B1, U2AF1 and SRSF2 in 118 patients with myelodysplastic syndromes and related diseases].
    Wang JY, Ma J, Lin YN, Wang J, Shen H, Gui FM, Han C, Li QH, Song Z, Wang XJ.
    Zhonghua Xue Ye Xue Za Zhi; 2017 Mar 14; 38(3):192-197. PubMed ID: 28395441
    [Abstract] [Full Text] [Related]

  • 7. Alteration of the SETBP1 gene and splicing pathway genes SF3B1, U2AF1, and SRSF2 in childhood acute myeloid leukemia.
    Choi HW, Kim HR, Baek HJ, Kook H, Cho D, Shin JH, Suh SP, Ryang DW, Shin MG.
    Ann Lab Med; 2015 Jan 14; 35(1):118-22. PubMed ID: 25553291
    [Abstract] [Full Text] [Related]

  • 8. Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes.
    Wu L, Song L, Xu L, Chang C, Xu F, Wu D, He Q, Su J, Zhou L, Xiao C, Zhang Z, Zhao Y, Chen S, Li X.
    Tumour Biol; 2016 Apr 14; 37(4):4633-40. PubMed ID: 26508027
    [Abstract] [Full Text] [Related]

  • 9. Effect of RNA splicing machinery gene mutations on prognosis of patients with MDS: A meta-analysis.
    Wang X, Song X, Yan X.
    Medicine (Baltimore); 2019 May 14; 98(21):e15743. PubMed ID: 31124956
    [Abstract] [Full Text] [Related]

  • 10. Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations.
    Hamilton BK, Visconte V, Jia X, Tabarroki A, Makishima H, Hasrouni E, Abounader D, Kalaycio M, Sekeres MA, Sobecks R, Duong Liu H, Bolwell B, Maciejewski JP, Copelan E, Tiu RV.
    Am J Hematol; 2016 Jun 14; 91(4):406-9. PubMed ID: 26799334
    [Abstract] [Full Text] [Related]

  • 11. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.
    Thol F, Kade S, Schlarmann C, Löffeld P, Morgan M, Krauter J, Wlodarski MW, Kölking B, Wichmann M, Görlich K, Göhring G, Bug G, Ottmann O, Niemeyer CM, Hofmann WK, Schlegelberger B, Ganser A, Heuser M.
    Blood; 2012 Apr 12; 119(15):3578-84. PubMed ID: 22389253
    [Abstract] [Full Text] [Related]

  • 12. Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML.
    Hirabayashi S, Flotho C, Moetter J, Heuser M, Hasle H, Gruhn B, Klingebiel T, Thol F, Schlegelberger B, Baumann I, Strahm B, Stary J, Locatelli F, Zecca M, Bergstraesser E, Dworzak M, van den Heuvel-Eibrink MM, De Moerloose B, Ogawa S, Niemeyer CM, Wlodarski MW, European Working Group of MDS in Childhood.
    Blood; 2012 Mar 15; 119(11):e96-9. PubMed ID: 22238327
    [Abstract] [Full Text] [Related]

  • 13. A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts.
    Janusz K, Del Rey M, Abáigar M, Collado R, Ivars D, Hernández-Sánchez M, Valiente A, Robledo C, Benito R, Díez-Campelo M, Ramos F, Kohlmann A, Cañizo CD, Hernández-Rivas JM.
    Leuk Res; 2017 May 15; 56():82-87. PubMed ID: 28222336
    [Abstract] [Full Text] [Related]

  • 14. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.
    Damm F, Kosmider O, Gelsi-Boyer V, Renneville A, Carbuccia N, Hidalgo-Curtis C, Della Valle V, Couronné L, Scourzic L, Chesnais V, Guerci-Bresler A, Slama B, Beyne-Rauzy O, Schmidt-Tanguy A, Stamatoullas-Bastard A, Dreyfus F, Prébet T, de Botton S, Vey N, Morgan MA, Cross NC, Preudhomme C, Birnbaum D, Bernard OA, Fontenay M, Groupe Francophone des Myélodysplasies.
    Blood; 2012 Apr 05; 119(14):3211-8. PubMed ID: 22343920
    [Abstract] [Full Text] [Related]

  • 15. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
    Zhu Y, Li X, Chang C, Xu F, He Q, Guo J, Tao Y, Liu Y, Liu L, Shi W.
    Leuk Res; 2016 May 05; 44():8-16. PubMed ID: 26970172
    [Abstract] [Full Text] [Related]

  • 16. Alteration of SF3B1 and SRSF2 Genes in Myelodysplastic Syndromes Patients in Upper Northern Thailand.
    Yimpak P, Tantiworawit A, Rattanathammethee T, Angsuchawan S, Laowatthanapong S, Tasuya W, Bumroongkit K.
    Asian Pac J Cancer Prev; 2019 Apr 29; 20(4):1215-1221. PubMed ID: 31030497
    [Abstract] [Full Text] [Related]

  • 17. Tumor suppressor microRNAs are downregulated in myelodysplastic syndrome with spliceosome mutations.
    Aslan D, Garde C, Nygaard MK, Helbo AS, Dimopoulos K, Hansen JW, Severinsen MT, Treppendahl MB, Sjø LD, Grønbæk K, Kristensen LS.
    Oncotarget; 2016 Mar 01; 7(9):9951-63. PubMed ID: 26848861
    [Abstract] [Full Text] [Related]

  • 18. Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression.
    Wu SJ, Tang JL, Lin CT, Kuo YY, Li LY, Tseng MH, Huang CF, Lai YJ, Lee FY, Liu MC, Liu CW, Hou HA, Chen CY, Chou WC, Yao M, Huang SY, Ko BS, Tsay W, Tien HF.
    Am J Hematol; 2013 Nov 01; 88(11):E277-82. PubMed ID: 23861105
    [Abstract] [Full Text] [Related]

  • 19. Splicing Factor Mutations in Cancer.
    Bejar R.
    Adv Exp Med Biol; 2016 Nov 01; 907():215-28. PubMed ID: 27256388
    [Abstract] [Full Text] [Related]

  • 20. Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts.
    Chen Z, Wang SA, Goswami M, Tang G, Routbort MJ, Patel KP, Luthra R, Medeiros LJ, Ok CY.
    Leuk Res; 2019 Nov 01; 86():106227. PubMed ID: 31557598
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.